The pharmaceutical industry’s policy environment is changing rapidly, and appropriate policy conclusions can only be drawn after developing an understanding of the market’s structure, the system of regulation, and the impact that regulations have on how pharmaceutical products are prescribed and purchased. On behalf of the innovative pharmaceutical industry, and as part of the Sector Inquiry conducted in Europe, CRA examined off-patent product competition in different European national markets and the impact of related policy changes over the last ten years. In “Lessons from the Sector Inquiry,” CRA reviews this effort and explains why the lessons of policy analysis are equally important for litigation and strategic considerations.
Busting a myth: Is achieving US drug prices in Europe impossible?
To answer this question, the authors searched for evidence in the individual countries. Germany and the UK, for example, are the two European countries where...